Q&A: Senesco's SNS01-T as a new approach to treating B-cell cancers that can be modified for all cancers
(Thomson Reuters ONE) -
Shares of emerging micro-cap Senesco Technologies (NYSE MKT: SNT) have started
to wake up after they reported on Monday on the progress of its Phase 1b/2a
study for the treatment of multiple myeloma, which is the subject of a poster
presented today at the 2012 Annual Meeting of the American Society of Clinical
Oncology.
The firm is not your typical biotech firm. They are engaged in the research and
development of genetic technologies that improve commercial agriculture-- and
treat major medical conditions in humans. While most, frankly, have been
skeptical that Senesco's platform technology would work. It appears that there
may be something going on scientifically, after all. The company's science is
based on the identification and characterization of specific genes that are
responsible for plant cell death (senescence) and for programmed cell death in
humans (apoptosis).
SNS01-T is a novel approach to cancer therapy that is designed to selectively
trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell
and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a
study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the
University of Arkansas for Medical Sciences in Little Rock, and the Mary Babb
Randolph Cancer Center in Morgantown, WV. What caused the excitement is the fact
that so far one patient has completed the 6 week dosing schedule. This patient's
disease was considered stable, no disease progression, based on key disease
markers including monoclonal protein when evaluated at the end of weeks 3 and 6.
Les Browne, Ph.D., President and Chief Executive Officer of Senesco has
commented further on the surprising findings and his exclusive in-depth
interview with BioMedReports is now available at:
http://www.biomedreports.com/2012060596196/qaa-sns01-t-is-a-new-approach-to-
treating-b-cell-cancers-that-can-be-modified-for-all-cancers.html
Healthcare investors and Biotech traders interested in accessing BioMedReports'
new complete database of clinical trials and upcoming FDA and world-wide
regulatory decisions which can be used to make more profitable trades and see
upcoming catalysts can go to:
http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly
via twitter at: http://twitter.com/BioMedReports
####
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news
and the entire Healthcare Sector of the market. BioMedReports is not paid or
compensated to report the news and developments of publicly traded companies.
They sell a premium product for subscribers and full disclosures and information
about the stocks and news mentioned in this news release is available at
BioMedReports.Com
Media Contacts Only:
Mary Davila, Assistant Editor, BioMedReports.Com
e-mail: info(at)biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioMedReports via Thomson Reuters ONE
[HUG#1617521]
Datum: 05.06.2012 - 18:41 Uhr
Sprache: Deutsch
News-ID 153401
Anzahl Zeichen: 3842
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 329 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Q&A: Senesco's SNS01-T as a new approach to treating B-cell cancers that can be modified for all cancers"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
